Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166906 | 0.86 | L3MBTL1 (0.46) | MAPTKMT2AATMTDP1L3MBTL1 | |
| SCHEMBL1684265 | 0.85 | RXFP1 (0.41) | MAPTKMT2ATP53AXLMEN1 | |
| SCHEMBL4156780 | 0.80 | MET (0.38) | MAPTKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL14541885 | 0.80 | MET (0.39) | MAPTTP53KDM4EALDH1A1HPGD | |
| SCHEMBL13778809 | 0.79 | CNR2 (0.48) | ALDH1A1HPGDLMNA | |
| SCHEMBL4166420 | 0.79 | LMNA (0.37) | MAPTKMT2ATP53MEN1KDM4E | |
| SCHEMBL4803423 | 0.78 | PDE1A (0.40) | MAPTKMT2AMEN1MAPK1KDM4E | |
| SCHEMBL4175427 | 0.78 | BRD4 (0.40) | MAPTKMT2AMEN1LMNAPRNP | |
| SCHEMBL4798568 | 0.76 | THRB (0.39) | MAPTPRNPPOLB | |
| SCHEMBL4805325 | 0.76 | CACNB4 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | claimed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| EP-1943249-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer Products Incorporated (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007039802-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039802-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, IMPA1, TYMP | MAPT 615/4885KMT2A 1368/4885ATM 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.